NASDAQ:EQ Equillium Q1 2026 Earnings Results & Report $1.30 -0.02 (-1.52%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$1.32 +0.01 (+1.15%) As of 10/14/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Equillium missed analyst earnings expectations in its Q1 2026 results, released May 13, 2026. The company reported EPS of -$0.06 versus the -$0.04 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 13, 2026TimeAfter Market ClosesConference Call4:00 PM ET Equillium EPS ResultsActual EPS-$0.06Consensus EPS -$0.04Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersEquillium Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsEquillium's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 11, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Equillium Q1 2026 Earnings FAQ Did Equillium beat earnings estimates for Q1 2026? Equillium (NASDAQ:EQ) reported earnings of -$0.06 per share for Q1 2026, missing the consensus estimate of -$0.04. The report was announced on Wednesday, May 13, 2026. When is Equillium's next earnings date? Equillium's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Equillium on the company's earnings history page. Equillium Earnings HeadlinesEquillium, Inc. Receives Australian Regulatory Clearance to Initiate First-In-Human Clinical Trial of Eq504October 7, 2026 | marketscreener.comMEquillium Gains Australian Nod For Phase 1 Study Of EQ504; Dosing In Nov'26October 7, 2026 | rttnews.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses. | Decentralized Masters (Ad)Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology ConferenceOctober 6, 2026 | globenewswire.comEquillium (NASDAQ: EQ) clears Australia for EQ504 dosingOctober 6, 2026 | americanbankingnews.comEquillium Gets Australian Clearance for Phase 1 Trial of Ulcerative Colitis Drug Candidate EQ504October 5, 2026 | finance.yahoo.comSee More Equillium Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Equillium? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Equillium and other key companies, straight to your email. Email Address About EquilliumEquillium (NASDAQ:EQ) is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company’s approach centers on modulating immune pathways involved in disease progression, with the goal of addressing conditions that have limited treatment options. Equillium’s lead product candidate is itolizumab, a monoclonal antibody that targets CD6, an immune-cell receptor involved in the regulation of T-cell activity. The company is evaluating itolizumab in immune-mediated conditions, including acute graft-versus-host disease and lupus nephritis. Equillium also has an earlier-stage pipeline that includes peptide-based therapies designed to inhibit inflammatory pathways such as interleukin-17. Founded in 2017 and headquartered in San Diego, California, Equillium has built its development programs through internal research and strategic collaborations, including an agreement with Biocon for rights related to itolizumab. As a clinical-stage company, Equillium’s activities are primarily focused on research, clinical development and advancing its pipeline toward potential regulatory approval.View Equillium ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
